| Similar Articles |
|---|
 |
The Motley Fool
June 10, 2008
Brian Lawler |
Allergan's Unblemished Deal Acquiring a niche acne drug from QLT provides clarity for both companies.   |
The Motley Fool
November 29, 2007
Brian Lawler |
QLT Goes on the Block QLT announced yesterday that it's in the preliminary stages of exploring a sale. |
The Motley Fool
October 29, 2007
Brian Lawler |
QLT in a Rut or Ready for a Comeback? QLT updates investors on its top drugs. |
The Motley Fool
June 8, 2007
Brian Lawler |
QLT Eats Itself The beleaguered specialty pharmaceutical opens up another share buyback plan. |
The Motley Fool
April 24, 2007
Brian Lawler |
Is the Worst Over for QLT? The biopharma announces another dismal quarter of declining sales for its top compound. |
The Motley Fool
April 25, 2005
Charly Travers |
Where Is QLT going? The drug maker's upcoming conference call needs to address the question. Shares are down 30% since the beginning of the year. Can QLT turn this around? |
The Motley Fool
July 17, 2007
Brian Lawler |
QLT Stays the Course Sales of QLT's Visudyne, a drug to treat macular degeneration, continue to plummet due to competition. QLT plans to try to resuscitate. |
The Motley Fool
August 31, 2007
Brian Lawler |
QLT Gets Reformulated Drug developer QLT announced that an EU approval will open new markets for the cancer drug that could edge out the competition by lowering overall medical costs. |
The Motley Fool
April 28, 2005
Charly Travers |
QLT's a Clutch Performer Pharma continues to deliver growth through difficult times. |
The Motley Fool
February 26, 2007
Brian Lawler |
Is QLT the Comeback Kid? The Canadian drugmaker updates investors on its outlook for 2007. |
The Motley Fool
January 28, 2011
Brian Orelli |
Value Investing, Biotech Style Biotech investors should regard every binary event as a varying degree of confidence in a positive or negative result. |
The Motley Fool
October 26, 2006
Brian Lawler |
QLT Quickly Losing Traction The biotech company gets hammered by a competitor's superior product. There was one bright spot in the quarter for QLT, though. Investors, take note. |
The Motley Fool
August 31, 2004
Charly Travers |
Hidden Value With QLT The market might overlook the drug maker's promising programs. Over the next six months, biotech investors should keep an eye on this one. |
The Motley Fool
March 31, 2008
Brian Lawler |
A Good Mix for QLT QLT takes one step closer toward a winning combination for those who suffer from macular degeneration. |
The Motley Fool
February 16, 2010
Brian Orelli |
For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward. |
The Motley Fool
January 22, 2007
Brian Lawler |
QLT's Sagging Sales The drug developer's macular degeneration treatment has seen declining sales. And as sales fall, so too does the percent of profits that QLT keeps. Investors, take note. |
The Motley Fool
March 29, 2005
Charly Travers |
A Biotech Value Play Sometimes you have to invest against the grain. Take a look at Canadian drug company QLT. |
The Motley Fool
January 21, 2005
Charly Travers |
Seeing the Value in QLT A narrow-minded market could be creating a great drug value. |
The Motley Fool
July 5, 2006
Brian Lawler |
Stay Away From QLT Competitive pressure on its top drug makes this company one investors should avoid. |
The Motley Fool
February 23, 2005
Charly Travers |
QLT Is Still a Value The market's concerns mean this Canadian drug company is being offered up at a great price. |
The Motley Fool
June 15, 2004
Charly Travers |
QLT Swallows Atrix Atrix Laboratories has been purchased by Canadian drug company QLT. For Atrix shareholders, the timing of this deal must be incredibly frustrating. |
The Motley Fool
September 12, 2006
Brian Lawler |
Those Buybacks at QLT Is the biopharmaceutical repurchasing shares to make itself more attractive for an acquisition? Investors, take note. |
The Motley Fool
January 3, 2005
Rich Duprey |
Eying Profits in Eye Sight Macular degeneration is proving to be a field with eye-popping potential. Manufactured by Pfizer and Eyetech, a tiny biotech that went public early last year, Macugen was recently approved by the FDA. |
